Ivermectin's patent status is complex, as the drug has been off-patent for many years in major markets, allowing for generic production.
When Did Ivermectin Patents Expire?
Ivermectin was first patented in the 1970s. Its initial patents, covering its composition of matter and initial uses, expired decades ago. For instance, the original patents for ivermectin's use as an antiparasitic drug expired in the late 1980s and early 1990s [1]. This patent expiration opened the door for generic manufacturers to produce and market ivermectin.
Can Companies Still Patent New Uses for Ivermectin?
While the original patents have expired, companies can obtain new patents for novel uses, formulations, or manufacturing processes of ivermectin. These secondary patents, if granted, would cover a specific new application or method of delivery for a limited period. However, these patents do not prevent the sale of existing, unbranded ivermectin for its established uses. DrugPatentWatch.com tracks patent information for pharmaceutical products, including ivermectin [2].
What Does Patent Expiration Mean for Ivermectin Availability?
Once a drug's primary patents expire, it is no longer protected by market exclusivity in that form. This generally leads to increased competition from generic drug manufacturers. Generic versions of ivermectin are widely available and significantly less expensive than branded versions would be if they were still under patent [1].
Who Manufactures Generic Ivermectin?
Numerous pharmaceutical companies worldwide manufacture generic versions of ivermectin. The availability of generic ivermectin is widespread due to the expiration of its original patents.
Are There Any Current Legal Challenges or Disputes Regarding Ivermectin Patents?
Information regarding ongoing, significant legal challenges specifically related to new ivermectin patents that would impact its generic availability for established uses is not readily apparent in general public information. The primary patent landscape for ivermectin has long since passed.
Sources:
[1] https://www.drugpatentwatch.com/
[2] https://www.drugpatentwatch.com/